Poway, CA (PRWEB) January 05, 2016
VetStem Biopharma, Inc. Founder and CEO, Dr. Robert Harman, to Speak at the International Canine Sports Medicine Symposium during the North American Veterinary Conference.
Robert Harman, DVM, Founder and CEO of Regenerative Veterinary Medicine Company VetStem Biopharma, Inc. is scheduled to speak at the International Canine Sports Medicine Symposium during the North American Veterinary Conference in Orlando, Florida January 16-20, 2016. Dr. Harman is scheduled to speak on the second day of the conference, Sunday, January 17 in the Sarasota Room at the Gaylord Palms Hotel beginning at 10:55am.
In his presentation titled “Practical Regenerative Medicine Protocols for the Canine Athlete” Dr. Harman will discuss how Regenerative Medicine can be used in the treatment of acute and chronic injuries in the canine athlete. He pulls from his biotechnology and veterinary experience to help VetStem perfect the clinical application of stem cell therapy for various types of injuries, illnesses, and other healing-promoting applications. VetStem is leading in the development for regenerative medicine in the veterinary field, with over 11,000 animals treated in the last 12 years.
This year International Canine Sports Medicine Symposium is taking place during the North American Veterinary Conference in Orlando, Florida. All those who are attending the NAVC will also be allowed to attend the two day session of the International Canine Sports Medicine Symposium. The ICSMS is hosted by the University of Florida’s Comparative Orthopaedics and Biomechanics Laboratory. The chair for the ICSMS is Daniel D. Lewis, DVM, Diplomate ACVS-Professor, Small Animal Surgery, with Kristin Kirkby Shaw, DVM, Diplomate ACVS and Justin Shmalberg, DVM, Diplomate ACVN-Clinical Asst. Professor, Integrative Medicine as co-chairs.
VetStem first pioneered adipose derived stem cell therapy for use in horses for tendon injuries, as an alternative to euthanasia. Just two years after the first horse was treated, VetStem treated the first cat and dog. In 2007 the first peer reviewed, randomized, double-blinded, placebo controlled, multi-center study was published showing intra-articular injection of autologous adipose derived stem cells in the hip joint of a dog decreased patient discomfort and increased patient functional ability. That same year VetStem brought to market the Genesis Platelet Rich Plasma concentration system, as well as the first formal small animal stem cell credentialing course. In 2015, VetStem (now VetStem Biopharma) has announced the successful completion of a pilot efficacy study for allogeneic stem cell therapy (90 dogs, multi-center, blinded, placebo controlled) in support of an FDA INAD. Primary end point was statistically significant. The study has been submitted for peer reviewed publication. VetStem also entered into a distribution and clinical research agreement with Pall LifeSciences, including exclusive distribution rights in the US and Canada on V-PET™ platelet enhancement therapy system. V-PET™ is the only veterinary platelet therapy system supported by JAVMA peer reviewed publication of a multi center, double-blinded, randomized study in dogs.
About VetStem Biopharma
VetStem Biopharma is a veterinarian lead company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 12 years and 11,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The company’s stated mission being “to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases”. In addition to its’ own portfolio of patents, VetStem holds exclusive global veterinary licenses to a portfolio of over 55 issued patents in the field of regenerative medicine.